Entegrion focuses on enhancing patient care through innovative technologies, particularly with its VCM™ (Viscoelastic Coagulation Monitoring) system. This point-of-care device offers rapid assessment of hemostasis, enabling healthcare providers to evaluate blood coagulation in a portable and chemistry-free format. Designed for near-patient use, the VCM™ system is particularly beneficial in emergency and critical care settings, where timely decision-making is crucial for patient outcomes.

In addition to the VCM™ system, Entegrion is actively pursuing regulatory clearances to expand its product offerings. The company has recently announced the CE Mark for its point-of-care system, which signifies compliance with European health and safety standards. This regulatory achievement underscores Entegrion's commitment to advancing blood coagulation monitoring technologies, ultimately aiming to improve patient care and outcomes in various clinical environments.

United States

Entegrion identifies, invents and systematically develops device and biological technologies to meet clearly defined medical needs. 

Our pipeline is distinguished by its uniqueness--- we pursue areas with limited competition and profound needs.  We design efficient and focused development plans to assure that the products we deliver perform as intended and are ready for market.

Twitter @entegrioninfo

Entegrion

Company Details